BNP Paribas Financial Markets’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-27,050
| Closed | -$303K | – | 4392 |
|
|
2017
Q3 | $303K | Buy |
27,050
+10,910
| +68% | +$120K | ﹤0.01% | 2250 |
|
|
2017
Q2 | $178K | Buy |
16,140
+5,658
| +54% | +$56.6K | ﹤0.01% | 2525 |
|
|
2017
Q1 | $103K | Buy |
10,482
+1,320
| +14% | +$13.2K | ﹤0.01% | 2487 |
|
|
2016
Q4 | $99K | Buy |
9,162
+2,144
| +31% | +$21.4K | ﹤0.01% | 2528 |
|
|
2016
Q3 | $71.9K | Sell |
7,018
-8,567
| -55% | -$93.3K | ﹤0.01% | 2267 |
|
|
2016
Q2 | $204K | Buy |
+15,585
| New | +$204K | ﹤0.01% | 1889 |
|
|
2016
Q1 | – | Sell |
-9,340
| Closed | -$85.9K | – | 3411 |
|
|
2015
Q4 | $85.9K | Sell |
9,340
-1,104
| -11% | -$9.24K | ﹤0.01% | 2442 |
|
|
2015
Q3 | $72.5K | Buy |
10,444
+6,318
| +153% | +$54.1K | ﹤0.01% | 2607 |
|
|
2015
Q2 | $40.5K | Buy |
4,126
+2,898
| +236% | +$26.4K | ﹤0.01% | 2618 |
|
|
2015
Q1 | $10.9K | Buy |
+1,228
| New | +$9.78K | ﹤0.01% | 2701 |
|
|
2014
Q4 | – | Sell |
-2,893
| Closed | -$19.9K | – | 3760 |
|
|
2014
Q3 | $19.9K | Buy |
2,893
+2,811
| +3,428% | +$16.8K | ﹤0.01% | 3169 |
|
|
2014
Q2 | $431 | Sell |
82
-345
| -81% | -$1.68K | ﹤0.01% | 3615 |
|
|
2014
Q1 | $2.04K | Sell |
427
-612
| -59% | -$2.96K | ﹤0.01% | 2653 |
|
|
2013
Q4 | $5.24K | Sell |
1,039
-14,039
| -93% | -$67.6K | ﹤0.01% | 3063 |
|
|
2013
Q3 | $76.4K | Sell |
15,078
-2,816
| -16% | -$15.7K | ﹤0.01% | 2462 |
|
|
2013
Q2 | $88.8K | Buy |
+17,894
| New | +$85.2K | ﹤0.01% | 2559 |
|
BNP Paribas Financial Markets's SCLN Position: Q4 2017 in Review
BNP Paribas Financial Markets sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 27,050 shares — an estimated $303K sold.
BNP Paribas Financial Markets first reported a position in SCLN in Q2 2013 and held it in 16 quarters. The position peaked at $303K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- BNP Paribas Financial Markets reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- BNP Paribas Financial Markets sold 27,050 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $303K.
- BNP Paribas Financial Markets first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 16 quarters.
- BNP Paribas Financial Markets's Sciclone Pharmaceuticals Inc position peaked at $303K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2017, filed 1 Feb 2018.